Iobitridol 300 compared to iopromide 300 - A double-blind randomized phase-III study of clinical tolerance in total body CT

Purpose, Material and Methods: The clinical safety of iobitridol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications. Each examination was rated as diagnostic or nondiagnostic and the image quality was noted. Nature, onset, intensity as well as outcome of each adverse reaction were recorded. Results: There was no significant difference in image quality and side effects be tween the contrast media. In this study, both iobitridol and iopromide provided excellent image qualify and a low rate of side effects. Conclusion: Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT.